Clinical Cancer Research Acceptance Rate

The AACR publishes a journal metrics page, but Clinical Cancer Research does not disclose a stable acceptance-rate figure on its public pages.

Third-party aggregators report varying estimates, but none have been confirmed by the AACR. The journal publishes twice monthly, providing substantial capacity for translational cancer research, but the editorial bar remains high.

What is stable is the editorial posture:

• CCR sits between Cancer Research (basic) and JCO (clinical) in the AACR portfolio
• the journal requires a translational angle: bench findings with clinical implications, or clinical data with mechanistic insight
• targeted therapies, biomarkers, drug resistance, immunotherapy, pharmacogenomics, and diagnostic innovation are core areas
• the AACR's journal selector tool helps authors find the right AACR venue

That translational identity is the real filter. Papers whose primary advance is purely mechanistic belong in Cancer Research; papers whose primary advance is a clinical trial result belong in JCO.

At triage, the editor is usually asking:

• does this study connect a laboratory finding to a clinical cancer application?
• is there a biomarker, therapeutic target, resistance mechanism, or diagnostic advance?
• would clinical oncologists find this relevant to patient management?
• does the work bridge the gap between basic cancer biology and clinical practice?

Papers that clearly occupy the translational space - with both laboratory depth and clinical relevance - survive triage at much higher rates.

For Clinical Cancer Research, the useful question is:

Does this study bridge the laboratory and the clinic in a way that could influence cancer treatment, diagnosis, or risk stratification?

If yes, the journal is a strong fit. If the paper is purely mechanistic or purely clinical without a translational bridge, the acceptance rate is not the constraint. The translational positioning is.

The common misses are:

• centering strategy around an unofficial percentage instead of checking translational fit
• submitting basic cancer biology without a clinical bridge (belongs in Cancer Research)
• submitting clinical trial results without mechanistic insight (belongs in JCO)
• ignoring the AACR journal selector tool, which routes manuscripts across the portfolio
• underestimating CCR's emphasis on therapeutic and diagnostic innovation

Those are positioning problems before they are rate problems.

If you are deciding whether to submit, these pages are more useful than an unofficial rate:

• Clinical Cancer Research cover letter
• Cancer Research acceptance rate (AACR basic science journal)
• Journal of Clinical Oncology acceptance rate (ASCO clinical trials)

Together, they tell you whether the paper occupies the right translational space, and whether a different oncology venue would be a cleaner first submission.

In our pre-submission review work evaluating manuscripts targeting Clinical Cancer Research, three patterns generate the most consistent desk rejections. Each reflects the journal's standard: translational cancer research that bridges the laboratory and the clinic with both scientific rigor and clinical relevance.

Basic cancer biology without a demonstrated clinical or translational bridge. Clinical Cancer Research describes its focus as "translational research that bridges the laboratory and the clinic." The failure pattern is a mechanistically excellent paper that characterizes a new oncogene, describes a new pathway in tumor progression, or identifies a new cancer cell biology mechanism, but does not demonstrate clinical relevance in the manuscript. A paper characterizing the mechanism by which a specific kinase promotes metastasis in cell lines, without any data from patient tumors, clinical correlation, or therapeutic implication, belongs in Cancer Research. AACR's journal selector routes these explicitly. Editors desk-reject them quickly because the translational gap is visible in the abstract: a strong mechanism section and a future-directions paragraph that says "this could be a therapeutic target" does not constitute the bridge CCR requires.

Translational claim with cell-line-only evidence and no patient data. CCR publishes work where the clinical angle is demonstrated, not asserted. The failure pattern is a paper reporting that a new drug combination, a new biomarker candidate, or a new resistance mechanism has been identified in 2-5 cancer cell lines, with excellent mechanistic characterization, but without patient-derived xenograft data, clinical tumor samples, patient cohort correlation, or any evidence beyond the cell culture model. These papers are often technically strong but systematically incomplete for the CCR standard. Reviewers ask: is this real in a patient? If the answer is only "maybe, in future work," the paper needs more data before CCR submission. The missing clinical validation is the blocking issue, not the quality of the cell biology.

Preclinical pharmacology study without the evidence package that supports a translational claim. CCR receives a high volume of papers reporting drug responses in cell lines and mouse models claiming translational relevance for new cancer therapies. The failure pattern is a drug study demonstrating activity in mouse xenograft models without dose-response data at clinically relevant concentrations, without pharmacokinetic data, and without comparison to standard-of-care drugs under the same conditions. A paper showing 50% tumor growth inhibition in a xenograft model at doses that are not clinically achievable, without comparison to existing therapies, and without any patient-derived data, does not support a translational claim. CCR reviewers apply a specific test: could this result be used to support an IND application or a clinical trial design? If not, the evidence package is insufficient. A CCR translational evidence package check can identify whether the translational evidence meets this standard before submission.

The honest answer to "what is the Clinical Cancer Research acceptance rate?" is that the AACR does not publish one, and third-party estimates should not be treated as precise.

The useful answer is:

• yes, this is a selective translational cancer journal
• no, a guessed percentage is not the right planning tool
• use translational positioning, clinical relevance, and the bench-to-bedside bridge as the real filter instead

If you want help pressure-testing whether this manuscript occupies the translational space CCR demands, a CCR translational space and bench-to-bedside evidence check is the best next step.

The acceptance rate for Clinical Cancer Research does not distinguish between desk rejections and post-review rejections. A paper desk-rejected in 2 weeks and a paper rejected after 4 months of review both count the same. The rate also does not reveal how acceptance varies by article type, geographic origin, or research area within the journal's scope.

Acceptance rates cannot predict your individual odds. A strong paper with clear scope fit, complete data, and solid methodology has substantially better odds than the headline number suggests. A weak paper with methodology gaps will be rejected regardless of the journal's overall rate.

Before submitting, a CCR translational evidence and desk-rejection risk check assesses desk-reject risk for your specific manuscript against this journal's editorial bar.